admin – Page 2505 – Get News Story

Solar Installation Bay Area and Fremont: Your Energy Solutions Back Custom Solar and Battery Systems with Years of Experience

The solar leader in the Bay Area since 2008, Your Energy Solutions delivers custom solar and battery storage with in-house expertise, brand-neutral tech, and unmatched local experience.

For reliable and professional solar installation Bay Area, one provider stands out for its high-performance, custom-fit renewable energy systems. Founded in 2008, Your Energy Solutions (YES) has distinguished itself through brand-agnostic technology recommendations, in-house installations, and hands-on customer service, setting a higher standard for solar installation Fremont, the Central Valley, and surrounding regions.

Founded by industry veteran Jim Gitas, YES is a trusted name with over 15 years in the industry. A key differentiator for YES is its commitment to in-house labor. From initial site surveys to final inspections, the company employs and trains its technicians, avoiding the delays and quality inconsistencies commonly experienced with subcontractors.

According to Gitas, unlike providers tied to specific manufacturers, YES is not tied to a single solar manufacturer, which allows it to recommend the best technology to its clients. Emphasizing brand-neutral designs based on each client’s unique site conditions, usage, and goals, YES incorporates top-tier equipment, including Enphase, Tesla, LG, SolarEdge, and more.

This Livermore-based company carries out thorough on-site evaluations before providing customers with a project quotation. The team assesses roof integrity, electrical panels, and shading to prevent underperformance or costly redesigns mid-installation. This approach also streamlines permitting and utility coordination, critical advantages under California’s evolving NEM 3.0 regulations.

Whether for a compact Fremont home or a sprawling Central Valley agricultural facility, the company’s deep familiarity with local codes and interconnection processes has led to a 98% approval rate on first-round permit submissions across Alameda, Contra Costa, and San Joaquin counties.

Known for transparent pricing and no-pressure consultations, YES has completed over 1,200 installations. The company further promotes the viability of solar solutions through its physical showrooms in Livermore and Manteca, where clients compare battery storage options and panel efficiencies in person.

“Backed by 25-year warranties and expert permit and inspection services, YES delivers site-specific residential and commercial energy systems that meet the client’s needs. Every roof and energy profile is different, and by remaining brand-neutral, we eliminate conflicts of interest and focus solely on what works best for the customer,” said Gitas.

For more information, visit: https://share.google/yQEpkyE1YVsR626xn

Prices for utility power are unpredictable, but with solar, costs are steady, predictable, and often much lower. For residents of the Bay Area or Central Valley considering solar, YES simplifies the decision to make the switch.

Offering zero-down payment options, YES designs systems for quick break-even, typically in just five to seven years. In almost all cases, monthly payments are lower than the current utility bill. Beyond solar panels, customers can expect a thorough energy analysis, customer-specific design, and expert advice directly from highly trained professionals, not sales scripts or call centers.

For local businesses seeking energy solutions to reduce costs, boost efficiency, and position their brands, YES offers commercial solar solutions for warehouses, shopping centers, and office buildings. The company has helped companies reduce monthly bills by 30% or more while also gaining tax advantages and public goodwill.

As the local power grid strains under the Bay Area’s growing energy requirements, blackouts are becoming prevalent in the summer, affecting neighborhoods from Livermore to Merced. YES pairs solar systems with premium energy storage, such as Tesla Powerwall or Enphase Encharge, to keep essentials running during blackouts and reduce energy costs by switching to stored energy during peak rate hours.

With well over a thousand installations completed since 2008, YES continues to expand its footprint across Northern California. Homeowners exploring solar installation in the Bay Area can expect transparent pricing, detailed proposals, and a 25-year warranty with comprehensive coverage on labor and equipment, surpassing industry norms.

About the Company:

Your Energy Solutions (YES) is a Livermore-based solar and battery storage provider serving the Bay Area and Central Valley since 2008. Specializing in residential and commercial installations, YES offers brand-agnostic solar panels, backup batteries, EV chargers, and energy efficiency upgrades. Unlike competitors, the company conducts on-site surveys, employs in-house installers, and maintains physical showrooms for hands-on customer education. With deep knowledge of local permitting, NEM 3.0, and utility processes, YES ensures seamless, high-performance systems backed by 25-year warranties.

Media Contact
Company Name: Your Energy Solutions
Contact Person: Jim Gitas
Email: Send Email
Phone: (888)?888?0711
Address:290 Rickenbacker Cir
City: Livermore
State: CA 94551
Country: United States
Website: https://www.yourenergysolutions.com/

Budget Mini Storage – East 2nd Street: Practical Options for Self-Storage Units in Prescott Valley, AZ

Budget Mini Storage – East 2nd Street offers secure, affordable self-storage in Prescott Valley, AZ, with 24/7 on-site management, drive-up access, and climate-controlled units for residential and business needs.

Residents and businesses searching for reliable self-storage units in Prescott Valley need look no further than Budget Mini Storage – East 2nd Street, a STORAGExperts property. The facility combines affordability, security, and convenience, making it a standout choice for storage solutions in the Tri-City area.

STORAGExperts is a leading provider of self-storage solutions, specializing in well-maintained facilities with a focus on customer satisfaction. With properties across multiple states, the company delivers secure, accessible, and affordable storage options.

Providing personalized support to meet individual storage needs, the management teams at STORAGExperts properties are known for their excellent customer service. Budget Mini Storage – East 2nd Street is no exception and is committed to a service charter that goes beyond maintaining a clean, well-organized facility with drive-up units that permit quick loading and unloading of materials. The interior units also enjoy climate-controlled options for sensitive items, including electronics, documents, and furniture.

Often touted by customers as the most accessible self-storage units in Prescott Valley, AZ, Budget Mini Storage – East 2nd Street is located strategically off East State Route 69. The facility offers a variety of unit sizes, catering to both short-term and long-term storage needs. Whether storing seasonal items, business inventory, or household belongings, clients can choose between drive-up and interior units for added flexibility.

A key differentiator, the Budget Mini Storage – East 2nd Street facility invests heavily in security features and services, including an on-site resident manager, ensuring round-the-clock oversight and immediate assistance when needed. This added layer of protection gives customers peace of mind knowing their belongings are kept safe.

For those seeking affordable, secure, and easily accessible self-storage units in Prescott Valley, AZ, Budget Mini Storage – East 2nd Street stands out as a trusted provider. With competitive pricing, exceptional service, and a prime location, the facility has emerged as a preferred choice for storage solutions in the region.

For more information, visit https://www.storagexperts.net/locations/east-2nd-street-prescott-valley-az-86314/

With a prime location and customer-focused service, Budget Mini Storage – East 2nd Street in Prescott Valley, AZ, is the ideal solution for residential and business storage needs, offering a variety of secure and affordable self-storage options to meet diverse needs.

Interior units start from as low as $58/month for a compact 5′ x 5′ space, featuring ground-floor access, unit alarms, and online payment convenience, with larger interior units, such as 5′ x 10′ and 10′ x 5′, ideal for storing boxes, furniture, or business inventory. For those needing more space, a 7.5′ x 10′ interior unit is available, providing extra room while maintaining climate-controlled protection. All units prioritize security with alarms and easy accessibility.

For customers requiring drive-up convenience, the facility offers exterior-access units with roll-up doors. A 10′ x 10′ drive-up unit is available for $156/month and includes a second month free promotion, while a slightly larger 7.5′ x 15′ unit is also available for rent. These spaces are perfect for quick loading and unloading of vehicles, tools, or seasonal items. All units include 24/7 security, ground-floor access, and flexible online payment options.

For reliable and affordable self-storage units in Prescott Valley, AZ, Budget Mini Storage – East 2nd Street delivers secure, well-maintained options with flexible terms. From compact interior units to convenient drive-up spaces, customers benefit from 24/7 security, online payments, and competitive pricing, including limited-time promotions. Located at 6701 E 2nd St, Prescott Valley, AZ 86314, the facility ensures a hassle-free storage experience with competitive pricing and well-maintained spaces.

About the Company:

Budget Mini Storage – East 2nd Street, a premier STORAGExperts facility in Prescott Valley, AZ, provides secure and affordable self-storage solutions with 24/7 on-site management. The property features a variety of unit sizes (5×5 to 10×20), including climate-controlled options and convenient drive-up access. Current promotions include 2nd-month-free specials on select units. Located at 6701 E 2nd St, the facility offers modern security features like unit alarms and online payment options. Serving residential and commercial clients, Budget Mini Storage stands out for its clean, well-maintained units and exceptional customer service in the region.

Media Contact
Company Name: Budget Mini Storage – East 2nd Street
Contact Person: Danielle Pancheri
Email: Send Email
Phone: +1 928-800-8711
Address:6701 E 2nd St
City: Prescott Valley
State: AZ 86314
Country: United States
Website: https://www.storagexperts.net/locations/east-2nd-street-prescott-valley-az-86314/

Roof Repair Milwaukee Company Acts As Claim Advocate To Maximize Insurance Coverage

Milwaukee-based Absolute Restorations offers comprehensive storm restoration services, complemented by expert insurance claims advocacy. The business model provides a unique pairing of services that ensures homeowners get full damage coverage they might not have known was available.

Absolute Restorations, under the leadership of Josh Lesley, is pleased to announce that the roof repair Milwaukee professionals provide fast, 24/7 emergency support after storms, fires, water, or mold disasters across Southeastern Wisconsin. Their inspections go beyond standard visual checks by documenting all storm impact with precision, using methods insurers recognize and reimburse. The company handles all restoration work in-house, including roofing, siding, gutters, windows, and interior damage repairs. Unlike most restoration contractors, Absolute Restorations acts as a claim advocate, meticulously documenting storm damage and presenting it to insurers to maximize coverage, often uncovering costs competitors miss.

Absolute Restorations is a storm and disaster restoration contractor based in Southeastern Wisconsin, operating under the leadership of Josh Lesley. With a reputation built on precision inspections, expert insurance documentation, and fast emergency response, the company has grown into a trusted provider of roofing, siding, windows, and complete property restoration services. The roofing Milwaukee professionals assist homeowners from the moment damage strikes through full repair and insurer reimbursement, ensuring clients are never left navigating the process alone.

The company’s emergency response and customer service are top-tier; clients frequently cite their clear communication, commitment to timelines, and ability to reduce out-of-pocket expenses. The company’s deep knowledge of Wisconsin weather patterns and insurance systems makes it more effective in identifying storm damage and securing rightful claim payouts. They offer full-service restoration in-house, eliminating the need for multiple contractors and ensuring accountability at every step.

Additional details are available at: https://share.google/RPXNVuS4GPvDoD3dS

Josh Lesley explained, “Our typical customers are middle- to upper-income homeowners in residential neighborhoods, or property managers in Southeastern Wisconsin, especially in cities like Milwaukee, Waukesha, Madison, Eagle, and Oconomowoc, who have experienced storm, hail, wind, or water-related damage to their property. We also assist owners of small commercial buildings. Our customers are seeking peace of mind during high-stress events and are often overwhelmed by the insurance claim process. They value honest contractors who communicate clearly, fight for their coverage, and deliver high-quality repairs fast.”

Absolute Restorations excels in managing insurance claims for storm damage. The precise damage assessments are meticulously documented to ensure homeowners have the robust evidence required to streamline insurance claims, aiding in a swift and favorable resolution.

The professional team is proficient in identifying damage caused by Wisconsin’s severe weather conditions, such as high winds, ice, and hail. They conduct exhaustive inspections to detect specific damage types. Utilizing industry-standard methodologies, the inspectors produce a comprehensive damage report, a vital tool in arming home and business owners with the necessary information to pursue insurance claims effectively.

The company’s focus extends to specialized inspections targeting hail damage, pivotal for substantiating insurance claims. The depth of detail captured in these inspections is crucial for illustrating the extent of damage to insurance providers, thereby justifying the need for repair coverage.

With expertise extending beyond restoration, the company makes the insurance claim process as straightforward as possible. By presenting a detailed and transparent report of damages, the customer has a solid foundation for the claim, demystifying the costs and necessary repairs. This approach not only expedites the insurance process but also maximizes the likelihood of receiving adequate funds for a complete restoration.

A comprehensive portfolio of services includes emergency water extraction, drying and dehumidification, structural repair, fire damage, and soot and smoke cleanup. The company can identify compromised materials during a structural assessment and rebuild for safety and longevity. The professional team responds quickly for mold remediation, removal, and preventative measures to reduce humidity and prevent recurrence.

About the Company:

Absolute Restorations offers an experienced professional team to provide restoration and remediation services across Southeastern Wisconsin. Since 2011, the company has been recognized as a trusted partner and contractor in home damage restoration. The team consists of dedicated professionals who are passionate about restoring properties and exceeding clients’ expectations. With a focus on professionalism and attention to detail, every restoration project is completed to the highest standards.

Media Contact
Company Name: Absolute Restorations
Contact Person: Josh Lesley
Email: Send Email
Phone: (414) 739-4251
Address:3500 S 92nd St
City: Milwaukee
State: WI 53228
Country: United States
Website: https://absolute-restorations.com/

Modern Builders Elevates Pasadena Roofing Standards With Multi-Trade Expertise and Generational Craftsmanship

Modern Builders revolutionizes Pasadena construction with multi-trade expertise, generational craftsmanship, and strong warranties, delivering seamless roofing, stucco, drywall, and painting under one roof.

Finding a contractor that delivers reliability, expertise, and long-term protection for roofing and construction projects can be a challenge. From stucco, drywall, and painting to roofing Pasadena and Los Angeles, Modern Builders is a multi-trade contractor providing integrated construction services to ensure seamless coordination from start to finish.

Unlike single-trade contractors, Modern Builders eliminates the hassle of hiring multiple specialists while maintaining consistent quality across all phases of a project. Whether repairing storm-damaged roofing or restoring a historic facade, the company’s comprehensive services save clients time and reduce logistical headaches.

With decades of combined experience, the team at Modern Builders blends old-school craftsmanship with cutting-edge materials and methods. As a family-run business, the in-house team leverages skills passed down through generations, ensuring meticulous attention to detail in every project. This legacy of excellence is particularly evident in its roofing solutions, where proper installation and material selection are critical for Southern California’s climate.

A key differentiator for Modern Builders is its commitment to warranty-backed work. The company offers a 10-year guarantee on roofing installations and a 5-year warranty on stucco applications, providing clients with confidence in the durability of their investments. In an industry where subpar workmanship can lead to costly repairs, these warranties underscore the company’s dedication to quality.

Specializing in roofing Los Angeles, Pasadena, and across the area, Modern Builders understands the unique challenges posed by the region’s architecture and weather patterns. Its familiarity with Southern California’s building codes and climate-driven repair needs ensures projects are not only aesthetically sound but also structurally resilient. From Spanish-style homes to modern commercial buildings, the team tailors its approach to meet the demands of local structures.

For property owners seeking a contractor that combines broad expertise, guaranteed workmanship, and generational know-how, Modern Builders provides top-tier exterior services under a single roof, offering proven solutions backed by transparent quotes with no hidden fees.

For more information, visit: https://share.google/tSoeeEQXE3Q06MTme

Modern Builders is a fully licensed and insured company in California, boasting over 25 years of hands-on experience in stucco, drywall, and painting projects of any size. Prioritizing the use of reliable high-end materials from GAF, Sherwin-Williams, and Parex USA, all projects are built to handle Pasadena’s harsh sun, seasonal rain, and Santa Ana winds.

Roofing is one of the most critical components of a house, providing structural strength and protection from the elements. Whether installing a new roof or repairing an existing one, Modern Builders offers more than a strong, weather-resistant roof to secure the home and everything within. With a selection of materials and colors available, highly skilled installation pros add style and curb appeal to any home.

Additionally, this company is “on call” to provide emergency repairs in the event of major leaks or roof damage. First, these expert roofers will determine the exact source of the leak before analyzing the issue and finding the fastest way to repair it. Such prompt action helps minimize damage and ensure homes remain protected.

A sturdy, fire-resistant material, drywall is ideal for building and a staple in almost every modern home. However, it is not immune to damage. Whether dealing with a dent from moving furniture or an unsightly series of holes left behind by a tradesman, Modern Builders makes plaster, sheetrock, and drywall look pristine and new again in less time and with less mess.

Complementing its roofing, drywall, and painting services, Modern Builders specializes in stucco exteriors, texture matching, re-flashing, and re-stuccoing. Stucco is a go-to solution for many homeowners when it comes to selecting a material for a home’s exterior. With various color options, stucco is a versatile and low-maintenance option that protects house exteriors while providing a clean-looking exterior finish.

Serving homeowners and businesses across Pasadena and Los Angeles, Modern Builders is a family-owned, full-service construction company specializing in roofing, stucco, drywall, and painting. A one-stop shop with a focus on multi-trade coordination, warranty-backed services, and generational craftsmanship, the company serves residential and commercial clients throughout the Greater Los Angeles area.

About the Company:

Modern Builders is a family-operated construction company based in Pasadena, specializing in roofing, stucco, drywall, and painting services across Los Angeles. With decades of generational expertise, the firm combines time-tested craftsmanship with modern techniques to deliver durable, high-quality results. Unlike single-trade contractors, Modern Builders offers one-stop solutions, ensuring seamless coordination from start to end. Deeply rooted in Southern California, Modern Builders understands the region’s unique architectural and climate challenges, making it a trusted choice for residential and commercial projects.

Media Contact
Company Name: Modern Builders
Contact Person: Bryan Peralta
Email: Send Email
Phone: (626)?737?0053
Address:3801 S. Michillinda Drive
City: Pasadena
State: CA 91107
Country: United States
Website: https://modernbuilderscali.com/

Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon

The Key Cancer Vaccines Companies in the market include – Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others.

DelveInsight’s “Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cancer Vaccines market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Vaccines Market Forecast

Some of the key facts of the Cancer Vaccines Market Report:

The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01.
In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries.
In August 2024, BioNTech launched global clinical trials for BNT116, an mRNA vaccine being developed as a potential treatment for non-small cell lung cancer (NSCLC). The vaccine utilizes the same mRNA technology that played a crucial role in the development of Covid-19 vaccines.
In February 2024, A cancer vaccine trial initiated by Moderna commenced in the UK, with researchers optimistic about ushering in a new era of treatments.
In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000.
Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK.
The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more.
Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others
Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others
Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation
The Cancer Vaccines market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics.

Cancer Vaccines Overview

Cancer vaccines are a type of immunotherapy designed to stimulate the body’s immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence.

Get a Free sample for the Cancer Vaccines Market Report:

https://www.delveinsight.com/report-store/cancer-vaccines-market

Cancer Vaccines Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cancer Vaccines Epidemiology Segmentation:

The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Cancer Vaccines
Prevalent Cases of Cancer Vaccines by severity
Gender-specific Prevalence of Cancer Vaccines
Diagnosed Cases of Episodic and Chronic Cancer Vaccines

Download the report to understand which factors are driving Cancer Vaccines epidemiology trends @ Cancer Vaccines Epidemiology Forecast

Cancer Vaccines Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cancer Vaccines Therapies and Key Companies

PROVENGE (sipuleucel-T): Dendreon Pharmaceuticals
CAN-2409: Candel Therapeutics
LB-LR1109: LG Chem and AVEO Oncology
DCVax-L: Northwest Biotherapeutics
IO102-IO103: IO Biotech
ITI-1000: Immunomic Therapeutics
EVX-01: Evaxion Biotech
CAN-2409: Candel Therapeutics
AST-301: Aston Sci
EVX-02: Evaxion Biotech

Discover more about therapies set to grab major Cancer Vaccines market share @ Cancer Vaccines Treatment Market

Cancer Vaccines Market Strengths

Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of cancer neoantigen vaccination strategies
Neoantigen-based Personalized Cancer Therapeutic Vaccines like Vigil and Tedopi along with few others can stimulate immune responses to checkpoint inhibitors even in patients that have previously failed conventional treatment regimes, thereby, addressing potential unmet needs of the market

Cancer Vaccines Market Opportunities

Rising incidence of cancer will provide a larger window of opportunity for these novel vaccines
Recurrence is very common in cancers even after proper treatment. This opens up new window for Neoantigen-based Personalized Cancer Therapeutic Vaccines to dominate the treatment regime

Scope of the Cancer Vaccines Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others
Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others
Cancer Vaccines Therapeutic Assessment: Cancer Vaccines current marketed and Cancer Vaccines emerging therapies
Cancer Vaccines Market Dynamics: Cancer Vaccines market drivers and Cancer Vaccines market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cancer Vaccines Unmet Needs, KOL’s views, Analyst’s views, Cancer Vaccines Market Access and Reimbursement

To know more about Cancer Vaccines companies working in the treatment market, visit @ Cancer Vaccines Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cancer Vaccines Market Report Introduction

2. Executive Summary for Cancer Vaccines

3. SWOT analysis of Cancer Vaccines

4. Cancer Vaccines Patient Share (%) Overview at a Glance

5. Cancer Vaccines Market Overview at a Glance

6. Cancer Vaccines Disease Background and Overview

7. Cancer Vaccines Epidemiology and Patient Population

8. Country-Specific Patient Population of Cancer Vaccines

9. Cancer Vaccines Current Treatment and Medical Practices

10. Cancer Vaccines Unmet Needs

11. Cancer Vaccines Emerging Therapies

12. Cancer Vaccines Market Outlook

13. Country-Wise Cancer Vaccines Market Analysis (2020–2034)

14. Cancer Vaccines Market Access and Reimbursement of Therapies

15. Cancer Vaccines Market Drivers

16. Cancer Vaccines Market Barriers

17. Cancer Vaccines Appendix

18. Cancer Vaccines Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon

Plumbing Automated Dominates with Performance-Based Growth System for Plumbing Businesses

Plumbing Automated successfully executes the rollout of its automated growth system, helping U.S. plumbers generate exclusive inbound calls and build loyal customer bases.

Plumbing Automated, a New York-based digital growth partner, has been dominating its nationwide performance-based marketing system for licensed plumbing companies. The company’s full-funnel approach combines qualified inbound lead generation with a customer retention framework designed to help plumbing businesses achieve predictable growth and long-term brand loyalty.

Plumbing Automated operates on a licensed, results-first model. Clients only pay when the system delivers measurable results – specifically, booked, qualified calls from local homeowners in need of plumbing services. This performance structure ensures alignment between the company and its clients, many of whom are looking to scale while avoiding the risks of traditional marketing retainers.

“We’re not here to sell clicks or impressions,” said founder and marketing strategist Dilan Lieberman. “Our mission is to help plumbers build thriving, predictable businesses – starting with quality calls and ending with customers who come back and refer their friends.”

Plumbing Automated’s primary offering is its Automated Growth System, which leverages Google Local Service Ads, digital targeting strategies, and AI-powered follow-up tools. According to the company, each client receives 100+ exclusive, pre-qualified calls per month. These leads are never shared, increasing conversion rates and ensuring that plumbing companies focus only on serious, local prospects.

In addition to call generation, the company provides a proprietary post-sale system called the 10/10 Customer Flow. This process is designed to convert one-time customers into repeat clients and long-term advocates. It uses automated communication, follow-up reminders, and referral incentives to keep the client’s brand top of mind with past customers – driving rebookings and word-of-mouth business.

“Lead volume is great, but if it doesn’t translate to real business – and ongoing customer relationships – it’s just noise,” Lieberman added. “Our 10/10 model fills that critical gap.”

Clients of Plumbing Automated report not just an increase in job volume, but a stronger local brand presence. One multi-truck plumbing company based in California attributed a doubling of monthly bookings to the system and said more than 60% of its new jobs now come from referrals.

Industry analysts have also taken notice. A U.S. home services expert noted that “Plumbing Automated is rewriting the rulebook for trades marketing by delivering measurable ROI and sustainable growth – not just temporary lead spikes.”

The company works exclusively with licensed plumbing business owners, including single-operator services and established multi-truck firms. Plumbing Automated is not designed for subcontractors or temporary side hustlers, but for professionals focused on long-term scaling.

Clients have access to clear reporting dashboards that track lead volume, conversion rates, repeat bookings, and referral sources. The company emphasizes transparency and performance, aiming to act as a true growth partner rather than a traditional agency.

“We measure our success in scheduled jobs, loyal customers, and smart ways to turn revenue into growth,” Lieberman said. “That’s what real growth looks like.”

As more trade businesses turn to digital solutions for client acquisition and retention, Plumbing Automated’s approach is positioning it as a leader in the space. With tens of thousands of leads delivered and thousands of repeat customers generated, the company is helping U.S. plumbers take control of their growth – and their future.

To learn more, visit https://plumbingautomated.com

Media Contact
Company Name: Plumbing Automated
Contact Person: Dilan Lieberman
Email: Send Email
Country: United States
Website: https://plumbingautomated.com/

Inflammatory Myositis Market Growth Projections 2024-2034: DelveInsight Analysis | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics, Eli Lilly

The Key Inflammatory Myositis Companies in the market include – CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others.

DelveInsight’s “Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Inflammatory Myositis, historical and forecasted epidemiology as well as the Inflammatory Myositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast

Some of the key facts of the Inflammatory Myositis Market Report:

The Inflammatory Myositis market size was valued ~USD 589 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In December 2024, argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the lives of individuals with severe autoimmune diseases, has announced its decision to advance the development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study for adults with idiopathic inflammatory myopathies (IIM or myositis). This decision follows an analysis of topline data from the Phase 2 portion of the trial. The ALKIVIA study will continue enrolling patients across three myositis subtypes: immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).
The market size across the 7MM is expected to grow at a CAGR of approximately 11.7%, driven by heightened disease awareness and the introduction of emerging therapies.
In 2023, Germany and Italy held the largest market sizes among EU countries, with USD 69 million and USD 47 million, respectively, while Spain had the smallest market size at USD 21 million.
Japan had a market size of USD 72 million in 2023, but this is expected to shift in the coming forecast period.
In 2023, there were approximately 188 thousand diagnosed cases of inflammatory myositis across the 7MM, with 92 thousand cases estimated to be from the US. These numbers are expected to rise over the forecast period.
The diagnosed prevalent cases of inflammatory myositis were classified into specific types: PM, DM, and IBM, with 76 thousand, 84 thousand, and 27 thousand cases respectively across the 7MM in 2023. These numbers are expected to rise by 2034.
In 2023, the age-specific cases of inflammatory myositis in the EU4 and the UK were categorized as follows: 3 thousand cases in individuals aged 0–17 years, 12 thousand in those aged 18–44 years, 25 thousand in the 45–64 age group, and 29 thousand cases in individuals aged 65 years and older.
In 2023, the diagnosed prevalent cases of inflammatory myositis in Japan were further categorized by gender, with 10 thousand cases in males and 15 thousand cases in females.
Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
The Inflammatory Myositis epidemiology based on gender analyzed that females are more susceptible to suffer from Inflammatory myositis when compared to the male population, in the 7MM
The Inflammatory Myositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.

Inflammatory Myositis Overview

Inflammatory myositis is a group of rare autoimmune disorders characterized by inflammation and weakness of the muscles. These conditions involve inflammation of the muscles (myositis), leading to muscle weakness, pain, and fatigue. There are several types of inflammatory myositis, including polymyositis, dermatomyositis, and inclusion body myositis, each with its own specific features and patterns of muscle involvement.

Get a Free sample for the Inflammatory Myositis Market Report:

https://www.delveinsight.com/report-store/inflammatory-myositis-im-market

Inflammatory Myositis Epidemiology

Inflammatory Myositis Epidemiology Segmentation:

The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Inflammatory Myositis
Prevalent Cases of Inflammatory Myositis by severity
Gender-specific Prevalence of Inflammatory Myositis
Diagnosed Cases of Episodic and Chronic Inflammatory Myositis

Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast

Inflammatory Myositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammatory Myositis Therapies and Key Companies

Dazukibart (PF-06823859): Pfizer
Hizentra: CSL Behring
Efgartigimod: Argenx
Brepocitinib: Priovant Therapeutics/Roivant
Ultomiris: Alexion Pharmaceuticals
PF-06823859: Pfizer
Daxdilimab: Horizon Therapeutics
Baricitinib: Eli Lilly and Company
Nipocalimab: Janssen Research & Development
PF-06823859: Pfizer
Froniglutide: Immunoforge Co. Ltd.
Infliximab: Schering-Plough
Lovaza: GlaxoSmithKline
Rituximab: Roche Pharma AG

Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Market

Inflammatory Myositis Market Strengths

The therapeutic landscape is prolific in determining the efficacy, safety, and tolerability of novel drugs in patients with IM and its various types.

Inflammatory Myositis Market Opportunities

The rising data on overall Inflammatory Myositis prevalence and its subtypes is expected to add significantly to the patient pool.

Scope of the Inflammatory Myositis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies
Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Inflammatory Myositis Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Myositis Market Access and Reimbursement

To know more about Inflammatory Myositis companies working in the treatment market, visit @ Inflammatory Myositis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Inflammatory Myositis Market Report Introduction

2. Executive Summary for Inflammatory Myositis

3. SWOT analysis of Inflammatory Myositis

4. Inflammatory Myositis Patient Share (%) Overview at a Glance

5. Inflammatory Myositis Market Overview at a Glance

6. Inflammatory Myositis Disease Background and Overview

7. Inflammatory Myositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Myositis

9. Inflammatory Myositis Current Treatment and Medical Practices

10. Inflammatory Myositis Unmet Needs

11. Inflammatory Myositis Emerging Therapies

12. Inflammatory Myositis Market Outlook

13. Country-Wise Inflammatory Myositis Market Analysis (2020–2034)

14. Inflammatory Myositis Market Access and Reimbursement of Therapies

15. Inflammatory Myositis Market Drivers

16. Inflammatory Myositis Market Barriers

17. Inflammatory Myositis Appendix

18. Inflammatory Myositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Myositis Market Growth Projections 2024-2034: DelveInsight Analysis | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics, Eli Lilly

Transdermal Growth Support Solutions Gain Traction as Parents Seek Height Management Before Growth Plate Closure

“Child wearing Hautuki transdermal growth patch”

Growth supplement patches like Hautuki are gaining popularity as parents seek pill-free alternatives. The transdermal market is expected to grow 12% annually over five years.

TDDS-Based Products Appeal to Parents Through Enhanced Convenience and Compliance

As parental interest in children’s height development continues to surge, transdermal patch-based growth support solutions are emerging as a compelling alternative to traditional oral supplements.

Child wearing Hautuki growth Support Pach

Search Volume Surge Reflects Growing Demand

Recent market analysis shows the pediatric growth supplement market expanded 15.2% year-over-year in the first half of 2024. Search terms like “patch-type growth supplements” and “transdermal absorption nutrients” have experienced exponential increases, with leading products such as ‘Hautuki‘ gaining word-of-mouth popularity among parents.

TDDS Technology Highlights Convenience Advantages

Transdermal Drug Delivery System (TDDS)-based patch products offer several distinctive advantages:

24-hour continuous absorption capability
Minimized gastrointestinal side effects
Reduced risk of missed doses
Decreased child resistance to treatment

Industry experts note, “Products like Hautuki and other patch-based solutions are driving continuous market expansion by simultaneously securing convenience and safety.”

Young child measuring height during the critical growth window before growth plate closure.

Medical Experts Emphasize Critical Growth Window

According to pediatric endocrinology experts, a child’s final adult height results from genetic factors (23%) and environmental factors (77%) including nutrition, sleep, and physical activity.

A pediatric endocrinologist from Seoul National University Hospital explained, “The period before growth plate closure, particularly from late elementary through early middle school years, represents the golden window for height development.”

Market Outlook

Health functional food research shows projected 12% average annual growth for the pediatric growth supplement market over the next five years. Industry experts anticipate that comprehensive care products integrating AI-based growth prediction and personalized nutrition will dominate future markets, with leading brands including Hautuki focusing development on these emerging trends.

Media Contact
Company Name: Glovertise
Contact Person: Erick
Email: Send Email
Phone: 01091916367
Address:38, Yeongdong-daero 112-gil #706
City: Gangnam-gu
State: Seoul
Country: Korea
Website: https://glovertise.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Transdermal Growth Support Solutions Gain Traction as Parents Seek Height Management Before Growth Plate Closure

Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech Research

The Key Asthma Companies in the market include – GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Cumberland Pharmaceuticals, Pulmatrix Inc., and others.

DelveInsight’s “Asthma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast

Some of the key facts of the Asthma Market Report:

The asthma market size in the 7MM was around ~USD 19,000 million in 2023, with expectations of growth throughout the forecast period from 2024 to 2034.
In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), successfully met the primary endpoints in two Phase III trials for asthma. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies demonstrated that Breztri provided statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA therapies. Both trials were randomized, double-blind, and included 4,434 patients with uncontrolled asthma to evaluate Breztri’s potential as an effective treatment option.
In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), successfully met the primary endpoints in two Phase III trials for asthma. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies demonstrated that Breztri provided statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA therapies. Both trials were randomized, double-blind, and included 4,434 patients with uncontrolled asthma to evaluate Breztri’s potential as an effective treatment option.
In February 2025, Enveda, a biotechnology company leveraging AI to transform natural compounds into innovative medicines, is excited to announce the expansion of its lead asset, ENV-294, into a second indication: asthma. Originally developed for atopic dermatitis, this novel therapy offers a groundbreaking approach to treating respiratory inflammatory conditions. To support this progress, Enveda has established an advisory board featuring top experts in asthma research and treatment.
In September 2024, Kinaset Therapeutics revealed plans for two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), as a treatment for patients with moderate to severe asthma and those with COPD
The market size in the 7MM is expected to grow at a compound annual growth rate (CAGR) of approximately 3.9%, driven by rising disease awareness and the introduction of new drugs.
In 2023, the UK had the largest market size among EU countries, totaling USD 1.3 million, whereas Spain had the smallest market size at USD 0.4 million.
The recent 2024 American Thoracic Society (ATS) conference addressed a wide range of asthma-related topics, from real-world experiences and biomarkers to pediatric asthma and innovative treatments. The conference highlighted significant advancements in asthma research and treatment, including clinical remission indicators and new therapies like inhaled JAK inhibitors and oral STAT6 degraders.
The patent protection for the syringe formulation of XOLAIR in the United States and Europe is anticipated to conclude between 2024 and 2025. Currently, there is no presence of generic competition in either the United States or the European Union.
CINQAIR possesses biological exclusivity in the United States until 2028 and is granted regulatory exclusivity in Europe until 2026.
The collective number of diagnosed prevalent cases of asthma in the 7MM was approximated to be 55 million cases in 2022. Among these cases, the adult population had the highest diagnosed prevalent cases, and this number is anticipated to rise by 2032.
As per the World Health Organization (WHO) in 2022, asthma represents a significant non-communicable disease impacting individuals across various age groups, with children being particularly susceptible. It stands as the most prevalent chronic ailment among children. In 2019, approximately 262 million individuals were affected by asthma, resulting in 455,000 deaths.
Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others
Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others
The Asthma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.

Asthma Overview

Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing. These symptoms often occur in response to triggers such as allergens, irritants, exercise, or respiratory infections.

Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/asthma-market

Asthma Epidemiology

Asthma Epidemiology Segmentation:

The Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Asthma
Prevalent Cases of Asthma by severity
Gender-specific Prevalence of Asthma
Diagnosed Cases of Episodic and Chronic Asthma

Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast

Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Asthma Therapies and Key Companies

GSK3511294 (Depemokimab): GlaxoSmithKline
Masitinib (AB07105): AB Science
PT010: AstraZeneca
Dexpramipexole Dihydrochloride: Areteia Therapeutics
ARS 1: ARS Pharmaceuticals, Inc.
MEDI3506 (tozorakimab): AstraZeneca
AZD1402 (PRS-060): Pieris Pharma/AstraZeneca
Atuliflapon (AZD5718): AstraZeneca
Amlitelimab: Sanofi
Rilzabrutinib: Sanofi
BOXABAN (Ifetroban): Cumberland Pharmaceuticals
RG6341 (GDC-6599): Genentech Research/Roche
CBP-201: Suzhou Connect Biopharmaceuticals
AVTX-002 (Quisovalimab): Avalo Therapeutics
MRx-4DP0004: 4D Pharma plc
SB010: Sterna Biologicals

Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape

Asthma Market Strengths

Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in asthma.

Asthma Market Opportunities

Availability of varied formulation types and convenient dosing schedules for more effective treatment.

Scope of the Asthma Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others
Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others
Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies
Asthma Market Dynamics: Asthma market drivers and Asthma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement

To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Asthma Market Report Introduction

2. Executive Summary for Asthma

3. SWOT analysis of Asthma

4. Asthma Patient Share (%) Overview at a Glance

5. Asthma Market Overview at a Glance

6. Asthma Disease Background and Overview

7. Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Asthma

9. Asthma Current Treatment and Medical Practices

10. Asthma Unmet Needs

11. Asthma Emerging Therapies

12. Asthma Market Outlook

13. Country-Wise Asthma Market Analysis (2020–2034)

14. Asthma Market Access and Reimbursement of Therapies

15. Asthma Market Drivers

16. Asthma Market Barriers

17. Asthma Appendix

18. Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech Research

Symbolsink Celebrates a Decade of Excellence in Stainless Steel Sink Manufacturing for North America

Symbolsink, Malaysia’s largest stainless steel sink manufacturer, is celebrating ten years of growth, innovation, and customer trust in the North American market. The family-owned company has established itself as a reliable supplier of high-quality drawn and handmade sinks, with a strong reputation for craftsmanship, service, and technological leadership.

Seizing Opportunities, Driving Steady Growth

The story of Symbolsink begins with a Malaysian family’s tradition and innovation. Leveraging years of experience in managing family businesses and a deep understanding of the kitchen and bathroom industry, the founder keenly identified industry shifts. In 2012, amid anti-dumping investigations on stainless steel sinks from China, Symbolsink established its first factory in Malaysia, with a dedicated focus on manufacturing drawn stainless steel sinks for the North American market.

From a standing start, the company has scaled its annual production capacity to 800,000 units. Its flagship model, the SS-3218S single-bowl sink, remains a top seller, with monthly sales consistently surpassing 15,000 units.

Backed by reliable quality and superior service, Symbolsink quickly gained market recognition, leading to sustained order growth. Symbolsink expanded with a second drawn sink factory in 2016, a third handmade sink factory in 2018, and further increased its handmade sink production capacity in 2022, creating a diversified product portfolio that covers both drawn sinks and handmade sinks, better serving the needs of North American customers.

Leading with Innovation and Quality

Since its inception, the pursuit of premium quality and innovative technology has helped Symbolsink expand and move forward.

Symbolsink is the first factory in Asia to utilize third-generation automated machines for producing drawn stainless steel sinks. These cutting-edge machines represent the latest technological advances in the industry, enabling Symbolsink to produce high-quality sinks with exceptional efficiency.

Symbolsink is also the first stainless steel sink factory to adopt non-through welding. Thanks to the workers’ exquisite craftsmanship, the sinks Symbolsink offers feature premium corner finishing, which gives them a beautiful, high-end look.

Most stainless steel sinks that Symbolsink produces are cUPC certified, fully compliant with North American market standards, and help customers be more competitive in project bidding.

All of Symbolsink’s three stainless steel sink factories are ISO-certified, which offers reliable product quality and standardized production management.

Thanks to its comprehensive production capabilities, standardized management systems, and consistently high output, etc, Symbolsink was the only stainless steel sink factory in Malaysia that passed rigorous on-site inspections by U.S. Customs officials in 2019.

Market Recognition Fuels the Future

A decade of consistent quality and service has earned Symbolsink widespread market trust. Customers not only value the sinks Symbolsink produces—but also the support and reliability behind them. Symbolsink successfully helps customers start or expand their sink business. The founder shared: “There is one customer who started to buy sinks from Symbolsink in 2015, and developed from a small company that sells only 2,000pcs of sinks annually to 30,000pcs now. And because of high customer satisfaction, old customers of Symbolsink continue recommending new customers to order sinks from Symbolsink.”

Looking ahead, the founder stated, “We will continue to focus on the North American market, delivering better products and services through innovation and quality improvement.” As part of this commitment, Symbolsink has already developed several patented products, set to launch soon, reinforcing its position as an industry innovator and trusted manufacturing partner.

About Symbolsink

Symbolsink is Malaysia’s leading stainless steel sink manufacturer, specializing in the North American market. With advanced technology and strict quality standards, the company offers a comprehensive range of drawn sinks, handmade sinks, and custom solutions.

Media Contact
Company Name: Symbolsink
Contact Person: Ketty Wang
Email: Send Email
Country: Malaysia
Website: https://www.symbolsink.com/